Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

xtremepicks.com: Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) Xtreme picks of the day!

Mon. May 18, 2009; Posted: 03:57 AM
Stocks RSS
May 18, 2009 (M2 PRESSWIRE via COMTEX) -- ISPH | Quote | Chart | News | PowerRating -- The team at Xtremepicks.com scans the US and Canadian markets looking for microcap companies which show promise and have unique niches and opportunities. We look at all sectors to provide investors with the best investment opportunities in search of the next multi-bagger. Join Now!

Today's news alerts include: Inspire Announces Presentations at American Thoracic Society Annual Meeting

Data Presented from Phase 3 Cystic Fibrosis Trial with Denufosol Tetrasodium

DURHAM, N.C., May 15, 2009 -- Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today Inspire scientists and collaborators will present data at the American Thoracic Society (ATS) annual meeting May 15 - 20, 2009 in San Diego, CA.

The oral poster presentation, "Phase 3 Study of Denufosol Tetrasodium for the Treatment of Cystic Fibrosis" (R.B. Moss, R.D. Anbar, R.W. Wilmott, M. Barnes, A.E. Schaberg, T.A. Durham, F.J. Accurso), will take place during the poster discussion session, "New Data Regarding Cystic Fibrosis," on Sunday, May 17, 2009 from 8:15 AM - 10:45 AM.

Inspire will also have five presentations related to preclinical work conducted with novel Rho kinase inhibitors in respiratory-related applications.

These posters will be available on Inspire's website, www.inspirepharm.com, following the conference.

About Inspire

Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire's goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical and scientific expertise. The most advanced compounds in Inspire's clinical pipeline are Prolacria(TM) for dry eye and denufosol tetrasodium for cystic fibrosis, which are both in Phase 3 development, and AzaSite(R) for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AzaSite for bacterial conjunctivitis, the co-promotion of Elestat(R) for allergic conjunctivitis and royalties based on net sales of Restasis(R) for dry eye. For more information, visit www.inspirepharm.com.

About Xtremepicks.com

Xtremepicks.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.

Xtremepicks.com is a leading stock website that provides free daily alerts on stocks that are moving up. xtremepicks.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@xtremepicks.com

Xtremepicks.com is an independent electronic publication that provides information on selected publicly traded companies. xtremepicks.com is not a registered investment advisor or broker-dealer. Xtremepicks.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.xtremepicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Inspire Pharmaceuticals (ISPH) click here. Inspire Pharmaceuticals (ISPH) has Short Term PowerRatings of 4. Details on Inspire Pharmaceuticals (ISPH) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [ISPH]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.